Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17849194 | 0.85 | MAPK8 (0.34) | MAPK8MAPK9MAPK10MAPK14CYP3A4 | |
| SCHEMBL18052610 | 0.84 | MAPK10 (0.41) | MAPK8MAPK9MAPK10MAPK14CYP3A4 | |
| SCHEMBL16623544 | 0.82 | MEN1 (0.32) | MAPK8MAPK9MAPK10MAPK14 | |
| SCHEMBL16623466 | 0.79 | MAPK8 (0.32) | MAPK8MAPK9MAPK10MAPK14 | |
| SCHEMBL18052611 | 0.78 | MAPK8 (0.33) | MAPK8MAPK9MAPK10MAPK14CYP2C9 | |
| SCHEMBL18052608 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL17849192 | 0.78 | RIPK1 (0.37) | — | |
| SCHEMBL16623468 | 0.75 | MPO (0.31) | MAPK8 | |
| SCHEMBL17849200 | 0.72 | CYP2A13 (0.39) | — | |
| SCHEMBL17849215 | 0.72 | CRBN (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DGAT2 2758/4885MAPK8 46/4885MAPK9 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.